Successful outcome at the Future of Swedish and Danish Life Science day

We wish to thank Kemivärlden Biotech and Medicon Village for Thursday’s event “The Future of Swedish and Danish Life Science”, many interesting areas within precision medicine and big data were covered, not least within genomics.

Life sciences and information technologies have become more and more connected to make patient’s life better; a perfect example on this is SenzaGen’s in vitro safety testing based on genomics. By argumenting on how the company’s GARD™ technology can improve patient’s life, and how the technology can contribute to establish a new industry standard for animal free safety testing, SenzaGen’s Chief Commercial Officer, Anna Chérouvrier Hansson, won the Dragons Den pitch at The Future of Swedish and Danish Life Science.

-We’re very happy and proud to be recognized as a game changer in the industry, contributing to a safer patient environment, says Anna.
The prize, a ticket to the One Nucleus Genesis conference in London will support SenzaGen’s development of coming closer to the goal of placing a new industry standard.


For more information
Anki Malmborg Hager, CEO
SenzaGen AB
Telephone: +46 768 284822